Hereditary ovarian cancer: Beyond the usual suspects

Gynecologic Oncology

Volumn 124, Issue 2, 2012, Pages 347-353

  Pennington, Kathryn P ^a   Swisher, Elizabeth M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PALB2 PROTEIN; RAD51C PROTEIN; RAD51D PROTEIN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER GENETICS; CANCER GROWTH; CANCER RISK; CANCER SUSCEPTIBILITY; COLON CANCER; COST; DISEASE COURSE; FAMILIAL CANCER; FANCONI ANEMIA; FRAMESHIFT MUTATION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOMICS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HEREDITARY OVARIAN CANCER; HISTOPATHOLOGY; HUMAN; MISMATCH REPAIR; OVARY CANCER; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; OVARIAN NEOPLASMS; RNA HELICASES;

EID: 84856015503     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.12.415     Document Type: Review

References (65)

1. C. Loveday, C. Turnbull, E. Ramsay, D. Hughes, E. Ruark, and J.R. Frankum Germline mutations in RAD51D confer susceptibility to ovarian cancer Nat Genet 43 2011 879 882
2. A. Meindl, H. Hellebrand, C. Wiek, V. Erven, B. Wappenschmidt, and D. Niederacher Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene Nat Genet 42 2010 410 414
3. T. Rafnar, D.F. Gudbjartsson, P. Sulem, A. Jonasdottir, A. Sigurdsson, and A. Jonasdottir Mutations in BRIP1 confer high risk of ovarian cancer Nat Genet 43 2011 1104 1107
4. A.D. D'Andrea Susceptibility pathways in Fanconi's anemia and breast cancer N Engl J Med 362 2010 1909 1919
5. T.R. Rebbeck, N.D. Kauff, and S.M. Domchek Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA1 mutation carriers J Natl Cancer Inst 101 2009 80 87
6. S. Zhang, R. Royer, S. Li, J.R. McLaughlin, B. Rosen, and H.A. Risch Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer Gynecol Oncol 121 2011 353 357
7. T. Pal, J. Permuth-Wey, J.A. Betts, J.P. Krischer, J. Fiorica, and H. Arango BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases Cancer 104 2005 2807 2816 (Pubitemid 41798292)
8. B.B. Roa, A.A. Boyd, K. Volcik, and C.S. Richards Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 Nat Genet 14 1996 185 187 (Pubitemid 26338801)
9. C. Oddoux, J.P. Struewing, C.M. Clayton, S. Neuhausen, L.C. Brody, and M. Kaback The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1% Nat Genet 14 1996 188 190 (Pubitemid 26338802)
10. J.P. Struewing, D. Abeliovich, T. Peretz, N. Avishai, M.M. Kaback, and F.S. Collins The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals Nat Genet 11 1995 198 200
11. E. Levy-Lahad, R. Catane, S. Eisenberg, B. Kaufman, G. Hornreich, and E. Lishinsky Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families Am J Hum Genet 60 1997 1059 1067 (Pubitemid 27194090)
12. R. Moslehi, W. Chu, B. Karlan, D. Fishman, H. Risch, and A. Fields BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer Am J Hum Genet 66 2000 1259 1272 (Pubitemid 30468783)
13. G. Hirsh-Yechezkel, A. Chetrit, F. Lubin, E. Friedman, T. Peretz, and R. Gershoni Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel Gynecol Oncol 89 2003 494 498 (Pubitemid 36687798)
14. M.C. King, J.H. Marks, J.B. Mandell New York Breast Cancer Study Group Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 Science 302 2003 643 646 (Pubitemid 37310920)
15. A. Antoniou, P.D. Pharoah, S. Narod, H.A. Risch, J.E. Eyfjord, and J.L. Hopper Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies Am J Hum Genet 72 2003 1117 1130 (Pubitemid 36530000)
16. J. Boyd, Y. Sonoda, M.G. Federici, F. Bogomolniy, E. Rhei, and D.L. Maresco Clinicopathologic features of BRCA-linked and sporadic ovarian cancer JAMA 283 2000 2260 2265 (Pubitemid 30246777)
17. D. Ford, D.F. Easton, M. Stratton, S. Narod, D. Goldgar, and P. Devilee Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium Am J Hum Genet 62 1998 676 689 (Pubitemid 28164626)
18. S.R. Lakhani, S. Manek, F. Penault-Llorca, A. Flanagan, L. Arnout, and S. Merrett Pathology of ovarian cancers in BRCA1 and BRCA2 carriers Clin Cancer Res 10 2004 2473 2481 (Pubitemid 38445709)
19. T. Walsh, S. Casadei, M.K. Lee, C.C. Pennil, A.S. Nord, and A.M. Thornton Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing Proc Natl Acad Sci USA 108 2011 18032 18037
20. H.A. Risch, J.R. McLaughlin, D.E. Cole, B. Rosen, L. Bradley, and E. Kwan Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer Am J Hum Genet 68 2001 700 710 (Pubitemid 32203724)
21. B.A. Werness, S.J. Ramus, R.A. DiCioccio, A.S. Whittemore, K. Garlinghouse-Jones, and I. Oakley-Girvan Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry Int J Gynecol Pathol 23 2004 29 34 (Pubitemid 38018234)
22. A. Chetrit, G. Hirsh-Yechezkel, Y. Ben-David, F. Lubin, E. Friedman, and S. Sadetzki Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer J Clin Oncol 26 2008 20 25
23. D. Yang, S. Khan, Y. Sun, K. Hess, I. Shmulevich, and A.K. Sood Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer JAMA 306 2011 1557 1565
24. P.M. Vencken, M. Kriege, D. Hoogwerf, S. Beugelink, M.E. van der Burg, and M.J. Hooning Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients Ann Oncol 22 2011 1346 1352
25. P.C. Fong, D.S. Boss, T.A. Yap, A. Tutt, P. Wu, and M. Mergui-Roelvink Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2009 123 134
26. S. Gad, V. Caux-Moncoutier, S. Pagès-Berhouet, M. Gauthier-Villars, I. Coupier, and P. Pujol Significant contribution of large BRCA1 gene rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments Oncogene 21 2002 6841 6847 (Pubitemid 35221927)
27. N. Puget, D. Stoppa-Lyonnet, O.M. Sinilnikova, S. Pages, H.T. Lynch, and G.M. Lenoir Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions Cancer Res 59 1999 455 461 (Pubitemid 29048883)
28. T. Walsh, S. Casadei, K.H. Coats, E. Swisher, S.M. Stray, and J. Higgins Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer JAMA 295 2006 1379 1388
29. M.A. Unger, K.L. Nathanson, K. Calzone, D. Antin-Ozerkis, H.A. Shih, and A.M. Martin Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing Am J Hum Genet 67 2000 841 850
30. F.B. Hogervorst, P.M. Nederlof, J.J. Gille, C.J. McElgunn, M. Grippeling, and R. Pruntel Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method Cancer Res 63 2003 1449 1453 (Pubitemid 36373627)
31. H. Hampel, J.A. Stephens, E. Pukkala, R. Sankila, L.A. Aaltonen, and J.P. Mecklin Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset Gastroenterology 129 2005 415 421 (Pubitemid 41096629)
32. E. Stoffel, B. Mukherjee, V.M. Raymond, N. Tayob, F. Kastrinos, and J. Sparr Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome Gastroenterology 137 2009 1621 1627
33. M.G. Dunlop, S.M. Farrington, A.D. Carothers, A.H. Wyllie, L. Sharp, and J. Burn Cancer risk associated with germline DNA mismatch repair gene mutations Hum Mol Genet 6 1997 105 110 (Pubitemid 27033972)
34. P. Watson, R. Bützow, H.T. Lynch, J.P. Mecklin, H.J. Järvinen, and H.F. Vasen The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer Gynecol Oncol 82 2001 223 228 (Pubitemid 32730595)
35. S.M. Weissman, C. Bellcross, C.C. Bittner, M.E. Freivogel, J.L. Haidle, and P. Kaurah Genetic counseling considerations in the evaluation of families for Lynch syndrome-a review J Genet Couns 20 2011 5 19
36. R.C. Niessen, R.M. Hofstra, H. Westers, M.J. Ligtenberg, K. Kooi, and P.O. Jager Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome Genes Chromosomes Cancer 48 2009 737 744
37. A.D. Auerbach Fanconi anemia and its diagnosis Mutat Res 668 2009 4 10
38. T. Taniguchi, and A.D. D'Andrea Molecular pathogenesis of Fanconi anemia: recent progress Blood 107 2006 4223 4233 (Pubitemid 43801344)
39. J.P. de Winter, and H. Joenje The genetic and molecular basis of Fanconi anemia Mutat Res 668 2009 11 19
40. Y. Kim, F.P. Lach, R. Desetty, H. Hanenberg, A.D. Auerbach, and A. Smogorzewska Mutations of the SLX4 gene in Fanconi anemia Nat Genet 43 2011 142 146
41. C. Stoepker, K. Hain, B. Schuster, Y. Hilhorst-Hofstee, M.A. Rooimans, and J. Steltenpool SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype Nat Genet 43 2011 138 141
42. N.G. Howlett, T. Taniguchi, S. Olson, B. Cox, Q. Waisfisz, and C. de Die-Smulders Biallelic inactivation of BRCA2 in Fanconi anemia Science 297 2002 606 609 (Pubitemid 34815345)
43. H. Farmer, N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, and T.B. Richardson Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921 (Pubitemid 40559006)
44. N. McCabe, N.C. Turner, C.J. Lord, K. Kluzek, A. Bialkowska, and S. Swift Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition Cancer Res 66 2006 8109 8115 (Pubitemid 44299177)
45. M. Swift, C.L. Chase, and D. Morrell Cancer predisposition of ataxia-telangiectasia heterozygotes Cancer Genet Cytogenet 46 1990 21 27 (Pubitemid 20164925)
46. A. Renwick, D. Thompson, S. Seal, P. Kelly, T. Chagtai, and M. Ahmed ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles Nat Genet 38 2006 873 875 (Pubitemid 44141653)
47. H.M. Hsu, H.C. Wang, S.T. Chen, G.C. Hsu, C.Y. Shen, and J.C. Yu Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex Cancer Epidemiol Biomarkers Prev 16 2007 2024 2032
48. C. Ghimenti, E. Sensi, S. Presciuttini, I.M. Brunetti, P. Conte, and G. Bevilacqua Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations Genes Chromosomes Cancer 33 2002 235 242 (Pubitemid 34130929)
49. S. Casadei, B.M. Norquist, T. Walsh, S. Stray, J.B. Mandell, and M.K. Lee Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer Cancer Res 71 2011 2222 2229
50. CHEK2 Breast Cancer Case-Control Consortium CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies Am J Hum Genet 74 2004 1175 1182
51. S. Seal, D. Thompson, A. Renwick, A. Elliott, P. Kelly, and R. Barfoot Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles Nat Genet 38 2006 1239 1241 (Pubitemid 44646283)
52. N. Rahman, S. Seal, D. Thompson, P. Kelly, A. Renwick, and A. Elliott PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene Nat Genet 39 2007 165 167 (Pubitemid 46184346)
53. A. Dansonka-Mieszkowska, A. Kluska, J. Moes, M. Dabrowska, D. Nowakowska, and A. Niwinska A novel germline PALB2 deletion in breast and ovarian cancer patients BMC Med Genet 11 2010 20 29
54. F. Vaz, H. Hanenberg, B. Schuster, K. Barker, C. Wiek, and V. Erven Mutation of the RAD51C gene in a Fanconi anemia-like disorder Nat Genet 42 2010 406 409
55. K.L. Bolton, J. Tyrer, H. Song, S.J. Ramus, M. Notaridou, and C. Jones Common variants at 19p13 are associated with susceptibility to ovarian cancer Nat Genet 42 2010 880 886
56. E.L. Goode, G. Chenevix-Trench, H. Song, S.J. Ramus, M. Notaridou, and K. Lawrenson A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24 Nat Genet 42 2010 874 881
57. H. Song, S.J. Ramus, J. Tyrer, K.L. Bolton, A. Gentry-Maharaj, and E. Wozniak A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2 Nat Genet 41 2009 996 1001
58. D.B. Goldstein Common genetic variation and human traits N Engl J Med 360 2009 1696 1698
59. J. McClellan, and M.C. King Genetic heterogeneity in human disease Cell 141 2010 210 217
60. P. Broca Traité des Tumeurs 1866 Asselin Paris
61. K. Bergfeldt, B. Rydh, F. Granath, H. Grönberg, L. Thalib, and H.O. Adami Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study Lancet 360 2002 891 894 (Pubitemid 35283831)
62. N.D. Kauff, N. Mitra, M.E. Robson, K.E. Hurley, S. Chuai, and D. Goldfrank Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families J Natl Cancer Inst 97 2005 1382 1384 (Pubitemid 41487806)
63. M. Meyerson, S. Gabriel, and G. Getz Advances in understanding cancer genomes through second-generation sequencing Nat Rev Genet 11 2010 685 696
64. The Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
65. S. Mazoyer, A.M. Dunning, O. Serova, J. Dearden, N. Puget, and C.S. Healey A polymorphic stop codon in BRCA2 Nat Genet 14 1996 253 254